TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma. Although doxorubicin is the most commonly-used chemotherapeutic agent in the world, idarubicin is recently in the spotlight after promising results of the in vitro and prospective single-arm studies. On the other hand, there are many reports showing that the type of chemotherapeutic agents does not significantly alter the efficacy of transarterial chemoembolization. This is a randomized-controlled trial to show the non-inferiority

Trial Details

NCT ID

NCT06114082

Phase

PHASE2

Sponsor

Seoul National University Hospital

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

• IDA-TACE
• DOX-TACE

Locations (sample)

• Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

• Adults aged 19 or above.
• Patients diagnosed with HCC either histologically and/or radiologically (LI-RADS 4 or 5).
• Patients with five or fewer tumors.
• Patients in which the largest tumor is 5 cm or less in diameter.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →